Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Peptide therapies should only be used under the supervision of a licensed healthcare provider. Always consult your physician before starting any new treatment.
If you have been researching peptide therapy for anti-aging, improved body composition, or better recovery, you have almost certainly encountered the CJC-1295 + Ipamorelin stack. This combination is the most widely prescribed growth hormone secretagogue protocol in integrative and anti-aging medicine, and for good reason — it offers a synergistic approach to boosting your body's natural growth hormone production without the risks associated with exogenous HGH.
This guide breaks down how each peptide works individually, why they are more effective together, dosing protocols, expected results, side effects, and where they stand with the FDA in 2026.
What Are Growth Hormone Secretagogues?
Growth hormone secretagogues (GHS) are compounds that stimulate your pituitary gland to release more of its own growth hormone (GH). Unlike synthetic HGH injections, which introduce exogenous hormone and can suppress your natural production, secretagogues work with your body's existing feedback mechanisms. This generally produces a more physiological, pulsatile GH release pattern with a lower side effect profile.
GH secretagogues fall into two main categories: GHRH analogs (like CJC-1295) and ghrelin mimetics (like Ipamorelin). Combining one from each category produces synergistic effects that neither achieves alone.
CJC-1295: The GHRH Analog
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It mimics the natural signal from the hypothalamus that tells the pituitary gland to produce and release growth hormone.
CJC-1295 with DAC vs. without DAC
CJC-1295 comes in two versions, and the distinction matters:
- CJC-1295 with DAC (Drug Affinity Complex): The DAC modification binds the peptide to albumin in the blood, extending its half-life to approximately 6–8 days. This creates a sustained elevation of GH levels rather than pulsatile release. While convenient (injections only needed 1–2 times per week), the constant GH elevation is less physiological and may increase side effects like water retention.
- CJC-1295 without DAC (also called Mod GRF 1-29): This version has a short half-life of approximately 30 minutes, producing a more natural pulsatile GH release. It is the version most commonly paired with Ipamorelin, as it allows for timed dosing that mimics natural GH secretion patterns. This is the version we focus on in this guide.
Most clinicians prefer CJC-1295 without DAC for the Ipamorelin stack because the pulsatile release pattern is closer to the body's natural rhythm and is associated with fewer side effects.
Ipamorelin: The Selective GH Releaser
Ipamorelin is a growth hormone-releasing peptide (GHRP) that mimics ghrelin, the "hunger hormone," at the pituitary gland. What makes Ipamorelin unique among GHRPs is its selectivity:
- Selective GH Release: Ipamorelin stimulates growth hormone release without significantly increasing cortisol or prolactin levels. Other GHRPs like GHRP-6 and GHRP-2 trigger cortisol and prolactin spikes, which can cause unwanted effects like increased appetite, anxiety, and hormonal imbalance.
- Dose-Dependent Response: GH release scales predictably with dose, providing more controllable outcomes.
- Minimal Desensitization: Unlike some GHRPs, Ipamorelin maintains its effectiveness over extended use periods with minimal receptor desensitization.
Why Stack Them Together?
The CJC-1295 + Ipamorelin combination produces synergistic GH release that exceeds what either peptide achieves alone. The mechanism is complementary:
- CJC-1295 amplifies the GHRH signal — it tells the pituitary gland to produce more growth hormone.
- Ipamorelin triggers the release of stored growth hormone from the pituitary.
Together, they increase both the production and release of GH, resulting in higher peak GH levels and a more robust pulsatile pattern. Research suggests the combination can produce GH pulses 2–3 times greater than either peptide used independently.
Dosing Protocols
The most commonly prescribed protocol:
- CJC-1295 (no DAC): 100 mcg per injection
- Ipamorelin: 200–300 mcg per injection
- Timing: Administered together via subcutaneous injection, typically 30–60 minutes before bed on an empty stomach (fasting for at least 2 hours prior). GH is naturally released in its largest pulse during deep sleep, so bedtime dosing amplifies this natural peak.
- Frequency: Once daily, 5–6 days per week. Some practitioners prescribe twice daily (morning and bedtime) for more aggressive protocols.
- Cycle Duration: Typical cycles run 8–16 weeks. Some practitioners advocate for 3–6 month protocols with periodic lab monitoring (IGF-1 levels).
Important Dosing Considerations
- Inject on an empty stomach — carbohydrates and fats blunt GH release.
- Avoid eating for 30–60 minutes post-injection to maximize the GH pulse.
- Maintain consistent injection timing for optimal results.
- Start at the lower end of dosing and titrate up based on response and provider guidance.
Expected Effects
Patients and practitioners report a range of benefits from the CJC-1295 + Ipamorelin stack:
- Improved Sleep Quality: Often the first benefit noticed, typically within the first 1–2 weeks. Deeper sleep, more vivid dreams, and waking feeling more refreshed.
- Enhanced Recovery: Faster recovery from workouts, reduced muscle soreness, and improved exercise capacity. Usually noticed within 2–4 weeks.
- Body Composition Changes: Gradual reduction in body fat (particularly visceral fat) and modest increases in lean muscle mass over 2–4 months. GH promotes lipolysis (fat breakdown) and protein synthesis.
- Skin and Hair Quality: Improved skin elasticity, reduced fine lines, thicker hair. These effects develop gradually over 2–6 months.
- Cognitive Benefits: Some users report improved focus, mental clarity, and mood, potentially related to improved sleep quality and GH's neuroprotective effects.
- Joint Health: GH stimulates collagen synthesis, which may improve joint comfort and tendon resilience over time.
Realistic Expectations: GH secretagogues produce more subtle, gradual effects compared to exogenous HGH. They will not produce dramatic overnight transformations. Consistency over months, combined with proper nutrition and exercise, is key to meaningful results.
Side Effects
The CJC-1295 + Ipamorelin stack is generally well-tolerated. Common side effects include:
- Water Retention: Mild fluid retention, particularly in the first 2–4 weeks. This usually stabilizes. Reducing sodium intake can help.
- Tingling/Numbness: Transient tingling in the extremities (hands and feet), related to GH's effects on peripheral nerves. Generally mild and resolves.
- Increased Hunger: Ipamorelin can mildly stimulate appetite through ghrelin receptor activation, though far less than GHRP-6.
- Injection Site Reactions: Mild redness or discomfort at the injection site.
- Headache: Occasional, typically in the first week of use.
- Vivid Dreams: Due to enhanced deep sleep. Generally considered a positive effect, though some find it disruptive initially.
Serious side effects are rare at standard dosing. However, excessive GH elevation over extended periods can theoretically contribute to insulin resistance, joint pain, or carpal tunnel-like symptoms. This underscores the importance of medical supervision and periodic blood work (IGF-1 monitoring).
FDA Status (2026)
Both CJC-1295 and Ipamorelin were affected by the September 2023 FDA Category 2 reclassification, which restricted their availability through compounding pharmacies. As of 2026, both peptides are among those returning to Category 1 status, restoring access through licensed compounding pharmacies with valid prescriptions.
Neither peptide is FDA-approved for any specific indication. They are prescribed off-label by physicians who specialize in anti-aging, regenerative, and integrative medicine. For the latest regulatory updates, see our FDA peptide reclassification guide.
Frequently Asked Questions
How long until I see results from the CJC-1295 + Ipamorelin stack?
Sleep improvements are often noticed within the first 1–2 weeks. Recovery benefits typically appear by weeks 2–4. Body composition changes (fat loss, lean mass gains) are more gradual and usually become apparent after 2–4 months of consistent use.
Should I use CJC-1295 with DAC or without DAC?
For the Ipamorelin stack, CJC-1295 without DAC (Mod GRF 1-29) is preferred by most practitioners because it produces a more natural pulsatile GH release and has fewer side effects than the sustained-release DAC version.
Can I use this stack while on TRT?
Yes, the CJC-1295 + Ipamorelin stack is commonly used alongside testosterone replacement therapy. GH and testosterone have complementary effects on body composition and recovery. Inform your prescriber about all concurrent therapies.
Will this stack suppress my natural growth hormone production?
Unlike exogenous HGH, GH secretagogues work through your natural feedback mechanisms and generally do not suppress endogenous GH production. However, periodic cycling and monitoring are still recommended.
Do I need blood work before starting?
Yes. Baseline and periodic IGF-1 levels, fasting glucose, and insulin levels are recommended. A comprehensive metabolic panel and hormonal assessment provide important context for dosing decisions and safety monitoring.
Considering growth hormone peptide therapy? Check our peptide therapy cost guide to understand pricing, or read our peptide safety guide for a complete safety overview.